- Home
- MMT vs AVTX Comparison
MMT vs AVTX Comparison
Compare MMT & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMT
- AVTX
- Stock Information
- Founded
- MMT 1987
- AVTX 2011
- Country
- MMT United States
- AVTX United States
- Employees
- MMT N/A
- AVTX N/A
- Industry
- MMT Trusts Except Educational Religious and Charitable
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- MMT Finance
- AVTX Health Care
- Exchange
- MMT Nasdaq
- AVTX Nasdaq
- Market Cap
- MMT 262.6M
- AVTX 248.3M
- IPO Year
- MMT N/A
- AVTX 2015
- Fundamental
- Price
- MMT $4.72
- AVTX $18.38
- Analyst Decision
- MMT
- AVTX Strong Buy
- Analyst Count
- MMT 0
- AVTX 9
- Target Price
- MMT N/A
- AVTX $30.14
- AVG Volume (30 Days)
- MMT 86.5K
- AVTX 406.9K
- Earning Date
- MMT 01-01-0001
- AVTX 11-07-2025
- Dividend Yield
- MMT 8.58%
- AVTX N/A
- EPS Growth
- MMT N/A
- AVTX N/A
- EPS
- MMT 0.30
- AVTX N/A
- Revenue
- MMT N/A
- AVTX $441,000.00
- Revenue This Year
- MMT N/A
- AVTX N/A
- Revenue Next Year
- MMT N/A
- AVTX N/A
- P/E Ratio
- MMT $15.33
- AVTX N/A
- Revenue Growth
- MMT N/A
- AVTX N/A
- 52 Week Low
- MMT $4.04
- AVTX $3.39
- 52 Week High
- MMT $4.70
- AVTX $19.41
- Technical
- Relative Strength Index (RSI)
- MMT 43.54
- AVTX 70.82
- Support Level
- MMT $4.65
- AVTX $16.77
- Resistance Level
- MMT $4.76
- AVTX $19.20
- Average True Range (ATR)
- MMT 0.05
- AVTX 1.56
- MACD
- MMT -0.01
- AVTX 0.25
- Stochastic Oscillator
- MMT 32.50
- AVTX 83.52
About MMT MFS Multimarket Income Trust
MFS Multimarket Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests a majority of its net assets in fixed-income securities, corporate bonds of the U.S and foreign issuers, U.S Government securities, foreign government securities, mortgage-backed and other asset-backed securities of U.S and foreign issuers, and debt instruments of issuers located in emerging market countries. The portfolio of investments comprises of different sector investments such as aerospace, airlines, automotive, chemicals, electronics, and others.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).